Neos Therapeutics Appoints Jerry McLaughlin as Chief Executive Officer
Mr. McLaughlin joins
Mr. McLaughlin’s appointment follows the mutual decision by
“We are very excited to have Jerry join
“Neos has a unique commercial franchise of three ADHD products with strong growth potential in a large market. I look forward to working with the whole team to increase the market share for these products, advance the development pipeline and contribute to the overall growth of the company at this next stage,” said
"For the last several years, it has been an exciting time leading
The compensation committee of
These stock options were or will be granted outside of Neos’ current stockholder-approved stock option and incentive plan, were or will be approved by the compensation committee of
About Neos Therapeutics
Neos Therapeutics, Inc. (Nasdaq:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the size of the company’s market, its ability to increase its market share, the commercialization of Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER, its marketing plans, the therapeutic potential of Neos’ products and the research and development plan for its potential product candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern the company’s expectations, strategy, plans or intentions. These forward-looking statements reflect Neos’ current views about its expectations, strategy, plans, prospects or intentions, which are based on the information currently available to Neos and on assumptions the company has made. Although the company believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, they can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the company’s control including, without limitation, its ability to market and sell its products, the inherent uncertainty of drug research and development, and other risks set forth under the caption “Risk Factors” in its most recently filed Annual Report on Form 10-K as updated by its subsequently filed other SEC filings, including its Quarterly Report(s) on Form 10-Q. Neos assumes no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Chief Financial Officer
Stern Investor Relations, Inc.